VTYX VENTYX BIOSCIENCES INC

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

  • Event: Jefferies Healthcare Conference

    Location: New York, NY

    Date: Wednesday, June 7, 2023

    Time: 11:30 AM ET
  • Event: Goldman Sachs 44th Annual Global Healthcare Conference

    Location: Dana Point, CA

    Date: Thursday, June 15, 2023

    Time: 8:40 AM PT

A webcast of each event will be available in the Investors and News section of the Ventyx website at . A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit .

Investor Relations Contact

Patti Bank

Managing Director

ICR Westwicke

(415) 513-1284



EN
31/05/2023

Underlying

VTYXVENTYX BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VENTYX BIOSCIENCES INC

 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Promine...

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial...

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors in H2VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Tri...

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on...

February 18, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healt...

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualD...

February 5, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clin...

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson’s disease expected in H1 2025 Cash, cash equivalents and marketable securities balance o...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch